ACI Worldwide, Inc. To Release Third Quarter 2023 Financial Results
ACI Worldwide (NASDAQ: ACIW), a global leader in mission-critical, real-time payments software, announced today that it will report its financial results for the third quarter of 2023 on November 2, 2023. Management will host a conference call at 8:30 a.m. Eastern Time to discuss these results.
Interested persons may access a real-time teleconference webcast at http://investor.aciworldwide.com/ or use the following number for dial-in participation: toll-free (888) 660-6377. Please provide your name, the conference name of ACI Worldwide, Inc. and conference ID 3153574.
ACI, ACI Worldwide, ACI Payments, Inc., ACI Pay, Speedpay and all ACI product/solution names are trademarks or registered trademarks of ACI Worldwide, Inc., or one of its subsidiaries, in the United States, other countries or both. Other parties' trademarks referenced are the property of their respective owners.
On June 29, the "Gather Great Wisdom to Shape the Future of Intelligent Manufacturing?Special Exhibition on Design Intelligence and High Quality Development", hosted by the China Academy of Art (CAA), opened at the National Museum of China in...
Intermap Technologies ("Intermap" or the "Company"), a global leader in 3D geospatial products and intelligence solutions, announces a new financing. The Company is offering up to a maximum of 4,300,000 Class "A" common shares of the Company...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...
Enterprises in Asia Pacific are moving toward software-defined networking (SDN) to make communication more secure and resilient and speed up business decision-making, according to a new research report published today by Information Services Group...
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal...